Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 281 to 290 of 797

TitleReference numberPublishedLast updated
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal)TA745
Selpercatinib for treating advanced thyroid cancer with RET alterationsTA742
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancerTA740
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA741
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitableTA739
Tofacitinib for treating juvenile idiopathic arthritisTA735
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapyTA736
Berotralstat for preventing recurrent attacks of hereditary angioedemaTA738
Secukinumab for treating moderate to severe plaque psoriasis in children and young peopleTA734
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)TA732

Results per page

  1. 10
  2. 25
  3. 50
  4. All